Wednesday, July 8, 2026

Drug profile · INN

sulfadiazine

sulfadiazine (SULFADIAZINE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — sulfadiazine
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

sulfadiazine (SULFADIAZINE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sulfadiazine
Brand SULFADIAZINE
Mechanism Bacterial dihydropteroate synthase inhibitor
Target Dihydropteroate synthase
Route ORAL
Formulation SUSPENSION

Mechanism of action

Bacterial dihydropteroate synthase inhibitor

Primary target: Dihydropteroate synthase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Silver Sulfadiazine Approved · United Therapeutics Europe · Superficial Partial Thickness Burn

Related & competitor drugs

  1. dapsone Dihydropteroate synthase 1 inhibitor
  2. sulfamethoxazole Bacterial dihydropteroate synthase inhibitor
  3. mafenide acetate Bacterial dihydropteroate synthase inhibitor
  4. silver sulfadiazine Bacterial dihydropteroate synthase inhibitor
  5. sulfacetamide sodium Bacterial dihydropteroate synthase inhibitor
  6. sulfadiazine sodium Bacterial dihydropteroate synthase inhibitor

Frequently asked questions

What is sulfadiazine?

sulfadiazine (SULFADIAZINE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sulfadiazine?

SULFADIAZINE is a marketed brand name for sulfadiazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sulfadiazine?

sulfadiazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.